medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2008, Number 1

<< Back Next >>

Rev Mex Oftalmol 2008; 82 (1)

Efecto de ketorolaco tópico en la reducción del grosor retiniano, en pacientes tratados con fotocoagulación por edema macular diabético

Lima GV

Language: Spanish
References: 28
Page: 28-33
PDF size: 47.51 Kb.


ABSTRACT

Purpose: to identify whether topical ketorolac after photocoagulation reduces foveal thickness 25% more than placebo, in patients with diabetic macular edema.
Methods: type 2 diabetics with macular edema were assigned to treatment with ketorolac (group 1) or placebo (group 2) during three weeks after photocoagulation. Central foveal thickness was measured before photocoagulation and three weeks later by optical coherence tomography. Mean central macular retinal thickness was compared before and after photocoagulation by Wilcoxon’s t.
Results. 56 eyes of 36 patients were evaluated (mean age 58.7), central foveal thickness before photocoagulation did not differ statistically between groups. In group 1 (n=29) central foveal retinal thickness changed from 136-635 µm (mean 233.5) to 113-508 µm (mean 193.2, difference 17.25%, p= 0.005); in group 2 (n=27) mean central foveal thickness changed from 126-499 µm (mean 223) to 112-399 µm (mean 212, difference 4.9%)
Conclusions: Topical ketorolac after photocoagulation was effective to increase the effect of photocoagulation in reducing central foveal thickness over 25% more than in patients treated with placebo. It still has to be determined whether anti-inflammatory therapy associated to photocoagulation has a long term effect on the final visual function.


REFERENCES

  1. Varma R, Torres M, Peña F, Klein R. The Los Angeles Latino Eye Study Group. Ophthalmology 2004; 111:1298-1306.

  2. Asociación Mexicana de Retina, Sociedad Mexicana de Oftalmología, Asociación Panamericana de Oftalmología. Resultados del Día Panamericano de detección de retinopatía diabética (3 de julio de 1999, día D). Rev Mex Oftalmol 2005;79:88-92.

  3. Gass JD. Stereoscopic atlas of macular diseases. (4a ed.), St Louis, Mosby-Yearbook; 1997.

  4. Lewis H, Ryan SJ, Medical and surgical retina. St. Louis, Mosby-Yearbook; 1994.

  5. Krohne TU, Fauser S, Kirchhof B, Joussen AM. Entstehungsmechanismen des diabetischen Makulaödems. Klin Monastblat Augenheilkd 2003; 220: 521-525.

  6. Funatsu H, Yamashita H, Sakata K y cols. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112:806-816.

  7. Donnelly R, Idris I, Forrester JV. Protein Kinase C and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004; 88:145-151.

  8. Frank RN. Diabetic retinopathy. NEJM 2004; 350:48-58.

  9. Fong DS, Aiello LP, Ferris FL, Klein L. Diabetic retinopathy. Diabetes care 2004; 27:25450-2553.

  10. Voo I, Mavrofrides EC, Puliafito CA. Clinical applications of optical coherence tomography for the diagnosis and management of macular diseases. Ophthalmol Clin North Am 2004;17:21-31.

  11. Leung CKS, Chan WM, Yung WH y cols. Comparison of macular and peripapillary measurements for the detection of glaucoma. Ophthalmology 2005; 112:391-400.

  12. Frank RN, Schulz L, Abe K, Lezzi R. Temporal variation in diabetic macular edema measured by optical coherence tomography. Ophthalmology 2004; 111: 211-217.

  13. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110:2386-2394.

  14. Massin P, Erginay A, Haouchine B, Mehidi AB, Paques M, Gaudric A. Retinal thickness in healthy and diabetic subjects measured using optical coherence tomography mapping software. Eur J Ophthalmol 2002; 12:102-108.

  15. Goebel W, Kretzchmar-Gross T. Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina 2002; 22:759-767.

  16. Hee MR, Puliafito CA, Duker JS, Reichel E y cols. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998; 105:360-70.

  17. Lattanzio R, Brancato R, Pierro L, Bandello F y cols. Macular thickness measured by optical coherence tomography (OCT) in diabetic patients. Eur J Ophthalmol 2002; 12:482-487.

  18. Brown JC, Solomon SD, Bressler SB, Schachat AP y cols. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004; 122:330-5.

  19. Sanchez-Tocino H, Alvarez-Vidal A, Maldonado MJ y cols. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588-1594.

  20. Álvarez Celorio MD, Fromow Guerra J, Guerrero Naranjo JL, Quiroz Mercado H. Correlación entre grosor macular y capacidad visual en pacientes con retinopatía diabética y edema macular clínicamente significativo. Rev Mex Oftalmol 2004; 78:230-236.

  21. Rodríguez CR, Tenorio MG. Vademécum Académico de Medicamentos Oftalmológicos. México, McGraw-Hill Interamericana; 2002.

  22. Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci 1996; 37:613-618.

  23. Moreno OR, Andrés RC, Júlvez LP, Llorens VP y cols. Capacidad antiinflamatoria del ketorolaco tópico en un modelo experimental de inflamación ocular. Arch Soc Esp Oftalmol 2000;75:333-338.

  24. Flach AJ, Jampol LM, Weinberg D y cols. Improvement in visual acuity in chronic apahakic and pseudophakic cystoid macular edema after treatment with 0.5% ketorolac tromethamine. Am J Ophthalmol 1991; 112:514-519.

  25. Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology 1999; 106:1656-1659.

  26. American Academy of Ophthalmology. Basic and clinical Science Course. Section 12, Retina and vitreous. San Francisco, the Foundation of the American Academy of Ophthalmology; 2004.

  27. Hardman JG, Limbird LE. Goodman & Gilman’s: The pharmacological basis of therapeutics. (10a ed), New York, McGraw-Hill; 2001.

  28. Rumelt S. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double masked, placebo-controlled clinical trial. Evidence Based Ophthalmology 2005; 6:92-94.




2020     |     www.medigraphic.com